BioCentury
ARTICLE | Clinical News

Cebranopadol: Phase III data

October 10, 2016 7:00 AM UTC

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary...